To determine whether increased CD36 S-acylation contributes to cardiac metabolic and contractile dysfunction in diabetes, we infused the zDHHC inhibitor CMA into diabetic hearts (Figure 6A). This evidence concerns the gene CD36 and diabetes mellitus.